Baric Transcribed Interview (Redacted) — page 115

DC.Scheduling@LexitasLegal.com neutralizing epitopes for the development of therapeutic antibodies in vaccines. But I have never been to Sri Lanka or the Philippines. I have been to Nicaragua for a meeting with a P01 that I had, and currently have with Eva Harris, that studies dengue virus pathogenesis. It studied dengue virus pathogenesis in children in Nicaragua for the past 20-some years. It's the longest-running natural infection cohort on dengue virus, which has identified a large number of important features associated with what drives pathogenesis, and has informed the vaccine development. Currently we're funded with Aravinda to develop next12 generation protein-designed vaccines against dengue. MS. SALAZAR: And what agency funds the work that you had done -- DR. BARIC: NIH. MS. SALAZAR: -- with Sri Lanka? DR. BARIC: Yes. MS. SALAZAR: Okay. Going back to PREEMPT, did you ever receive any funding through the PREEMPT program, either as a direct awardee, subcontractor, subawardee? DR. BARIC: This is the PREEMPT -- MS. SALAZAR: The PREEMPT -- DR. BARIC: This is a DARPA grant we're talking about? No, I never have. MS. SALAZAR: Autonomous -- ATI?